Sign In
Buy CERE
$44.96
+0 (+0%)
At Close: Oct 30, 2024
Wall Street Analysts Think Cerevel Therapeutics Holdings, Inc. (CERE) Could Surge 27.31%: Read This Before Placing a Bet
11:17am, Monday, 06'th Nov 2023
The mean of analysts' price targets for Cerevel Therapeutics Holdings, Inc. (CERE) points to a 27.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, str
Cerevel Therapeutics to Report Third Quarter 2023 Financial Results and Business Updates on Wednesday, November 1, 2023
06:30am, Friday, 13'th Oct 2023
CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced
Cerevel Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
06:30am, Tuesday, 29'th Aug 2023
CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that me
Why Shares of Cerevel Therapeutics Are Dropping Wednesday
10:47am, Wednesday, 02'nd Aug 2023
Cerevel said it is experiencing delays in some of its clinical trials. The company appointed a new CEO in June.
Cerevel Therapeutics to Report Second Quarter 2023 Financial Results and Business Updates on Wednesday, August 2, 2023
06:30am, Wednesday, 05'th Jul 2023
CAMBRIDGE, Mass., July 05, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced
Cerevel: High Priced Stock Doing Interesting Science
06:38am, Sunday, 04'th Jun 2023
Cerevel has some interesting data in various CNS indications. However, the company has a very high valuation. It seems a lot of the company's potential is baked into its price.
Cerevel Therapeutics Holdings, Inc. (CERE) Q1 2023 Earnings Call Transcript
05:12am, Sunday, 07'th May 2023
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE ) Q1 2023 Earnings Conference Call May 3, 2023 8:00 AM ET Company Participants Matthew Calistri - Vice President, Corporate Strategy and Investor Relat
Cerevel Therapeutics to Present at the BofA Securities 2023 Health Care Conference
06:30am, Wednesday, 26'th Apr 2023
CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced
Cerevel Therapeutics to Report First Quarter 2023 Financial Results and Business Updates on Wednesday, May 3, 2023
06:30am, Tuesday, 11'th Apr 2023
CAMBRIDGE, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announce
Cerevel Therapeutics to Present at the Stifel 2023 CNS Days
06:30am, Tuesday, 21'st Mar 2023
CAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced
Cerevel Therapeutics to Present at the 43rd Annual Cowen Health Care Conference
06:30am, Thursday, 02'nd Mar 2023
CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced
Cerevel Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates on Wednesday, February 22, 2023
06:30am, Wednesday, 01'st Feb 2023
CAMBRIDGE, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced
Cerevel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference and Provide Pipeline Update
06:30am, Monday, 09'th Jan 2023
Initiated Phase 1 healthy volunteer trial to support development of emraclidine in Alzheimer's disease psychosis in Q4 2022; second potential indication as a once-daily treatment
Cerevel Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
06:30am, Wednesday, 04'th Jan 2023
CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced t
Cerevel Therapeutics Holdings, Inc. (CERE) Q3 2022 Earnings Call Transcript
12:43am, Sunday, 13'th Nov 2022
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE ) Q3 2022 Earnings Conference Call November 8, 2022 8:00 AM ET Company Participants Matt Calistri - Vice President of Corporate Strategy and Investor R
